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Highlights of “Biomarkers associated with sedentary behaviour in 
older adults: a systematic review” 
 
 Focus on the relationship of sedentary behaviour and biomarkers especially in 
older people aged 60 or above. 
 
 Intensive summary of all available information not only biochemical biomarkers 
but also performance biomarkers etc. 
 
 Clear separation between sedentary behaviour and simple lack of physical 
activity. 
 
 Objective assessment of results by categorisation with CADTH tool* 
 
 Results almost exclusively cardio-metabolic biomarkers; only few inflammation 
and performance biomarkers were evaluated too 
 
*for more details please see: https://www.cadth.ca/interventions-directed-professionals 
 
Abstract (word count 247/250) 
Objective: Pathomechanisms of sedentary behavior (SB) are unclear. We conducted a 
systematic review to investigate the associations between SB and various biomarkers in older 
adults. 
Methods: Electronic databases were searched (MEDLINE, EMBASE, CINAHL, AMED) up to July 
2015 to identify studies with objective or subjective measures of SB, sample size ≥ 50, mean 
age ≥ 60 years and accelerometer wear time ≥3 days. Methodological quality was appraised 
with the CASP tool. The protocol was pre-specified (PROSPERO CRD42015023731). 
Results: 12701 abstracts were retrieved, 275 full text articles further explored, from which 249 
were excluded. In the final sample (26 articles) a total of 63 biomarkers were detected. Most 
investigated markers were: body mass index (BMI, n=15), waist circumference (WC, n=15), 
blood pressure (n=11), triglycerides (n=12) and high density lipoprotein (HDL, n=15). Some 
inflammation markers were identified such as interleukin-6, C-reactive protein or tumor 
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necrosis factor alpha. There was a lack of renal, muscle or bone biomarkers. Randomized 
controlled trials found a positive correlation for SB with BMI, neck circumference, fat mass, 
HbA1C, cholesterol and insulin levels, cohort studies additionally for WC, leptin, C-peptide, 
ApoA1 and Low density lipoprotein and a negative correlation for HDL. 
Conclusion: Most studied biomarkers associated with SB were of cardiovascular or metabolic 
origin. There is a suggestion of a negative impact of SB on biomarkers but still a paucity of high 
quality investigations exist. Longitudinal studies with objectively measured SB are needed to 
further elucidate the pathophysiological pathways and possible associations of unexplored 
biomarkers. 
 
Key words: older adults, sedentary behaviour, biomarker 
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Introduction 
 
According to the National Institute of Health (NIH) Biomarkers Definitions Working Group4, a biomarker 
is a characteristic that is objectively measured as an indicator of normal biological processes, pathogenic 
processes, or a pharmacological response to a therapeutic intervention. Therefore, biomarkers can be 
very helpful as surrogate markers for diseases or pathophysiological links between exposure and 
disease; or as intermediate measures of the effectiveness of interventions on disease processes. Within 
the past few decades, a considerable amount of literature has clearly demonstrated that physical 
activity (PA) has a range of benefits on the health1,2 and wellbeing of older adults3. Recently, there has 
been an interest in understanding the biomarkers underlying the response to PA. For example, in a 
cohort of community dwelling older adults, levels of N-terminal pro-brain natriuretic peptide (NT-
proBNP) and high-sensitive troponin T have been associated with objectively monitored PA and showed 
a more beneficial profile with increasing PA, suggesting a dose response relationship7,8. To date, most of 
the PA biomarker research has focussed on cardiovascular risk factors5,6,7, but there are many other 
biological systems with associated biomarkers which may be affected by PA or especially SB. Recent 
examples include β-amyloid burden and glucose metabolism as markers of neurodegeneration18, 
interleukin-6 (IL-6) and C-reactive protein (CRP) as markers for systemic inflammation19 or DNA-repair as 
a marker for cell homeostasis20.  
An emerging evidence base has started to demonstrate that sedentary behaviour (SB), over and above 
time spent in PA, is independently associated with several important detrimental health outcomes, 
including endpoints such as mortality, frailty, sarcopenia, dementia, and cardiovascular diseases9. 
According to the Sedentary Behaviour Research Network, SB is defined as any waking behaviour 
characterised by an energy expenditure ≤ 1.5 metabolic equivalents (METs) whilst in a sitting or 
reclining posture10. The emerging research highlighting the deleterious impact of SB on health is of 
particular concerns as adults spend on average 5 hours of their time in sedentary behaviour11. Indeed, 
some studies have demonstrated that on the population-level sedentary time (ST) increased over the 
decades from 1960-201012. Especially older people spent most of their time in SB. A recent meta-
analysis illustrated that older people were sedentary for 65-80% of their waking time13, other sources 
mentioned ST with an average of 9 hours14 to 13.8 hours per day15. Older people are seen as the age 
group engaging in the highest level of SB13 and thus could benefit most from changing their daily habits. 
The developing evidence on the harms associated with SB has illustrated that it is not only the absence 
of daily or weekly moderate-to-vigorous physical activity (MVPA), but rather, SB is a separate category 
of behaviour with unique determinants, consequences and sequences for possible intervention16. 
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Considering the physiological changes occurring with age in several organ systems17, results from 
middle-aged adults can’t be simply transferred to older adults. Therefor the EU study SITLESS 
investigates how SB can be reduced sustainably and how sedentariness effects biomarkers especially in 
older adults. In this framework the interest on outcomes of studies performed in elderly, assessing SB 
and its impact on biomarkers was the focus. In addition, biomarker studies are important to further 
understand the link between SB, PA and adverse health outcomes like total mortality and harmful 
phenotypes like Metabolic Syndrome (MES)21, frailty or sarcopenia. Perhaps it can help to understand 
the role of biomarkers as possible mediators of the association between SB and adverse phenotypes or 
aging-related diseases. Therefore, the aims of this systematic review were to provide a comprehensive 
overview of aging-related biomarkers associated with SB and report on the strength of the observed 
associations in community-dwelling older adults. 
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Methods 
Study design  
This systematic review adhered to the PRISMA guidelines22 and followed a predetermined published 
protocol (PROSPERO No. CRD42015023731)23. 
 
Condition or domain being studied 
SB, as defined by the Sedentary Behaviour Research Network10 (waking behaviour with an energy 
expenditure ≤ 1.5 METs whilst in a sitting or reclining posture), represented our exposure of interest. 
We also considered studies which did not fully comply with this definition (e.g. television watching time, 
SB identified by other questionnaires or accelerometer data that do not allow for disentangling posture 
issues or clearly indicate METs) but are highly relevant to SB. 
With respect to the biomarkers we were interested in any inflammatory, renal and cardiac biomarkers, 
lipids and metabolic markers, genetic and metabolomics markers, endocrine markers and markers of 
muscle strength, body composition, as well as of specific physical performance measures (e.g. gait 
speed and balance).  
 
Information sources and searches  
Two authors (KW, BS) searched the electronic databases: MEDLINE (PubMed), EMBASE, CINAHL (via 
EBSCO), AMED (via Ovid/EBSCO) from inception to 15 July 2015. We used search terms described in 
appendix 1. Appropriate search strategies and MESH-terms were selected (see appendix 1). 
 
Study selection and eligibility criteria 
Studies meeting the following criteria were included:  
1) Explicitly measured SB using objective (accelerometer wear time ≥ 3 days (to follow the 
recommendations of good clinical practice24) or self-report instruments. Studies defining SB purely as a 
lack of PA were excluded.   
2) Including community dwelling, older adults (mean age of sample ≥ 60 years).  
3) Sample size of n ≥ 50 participants, to ensure adequate power.  
4) Quantitative study design including randomized controlled trials (RCTs), controlled clinical trials 
(CCTs), pre- and post-intervention measurement studies, prospective observational studies (POS), or 
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studies (only prospective trials) that examined an association of any biomarker with SB. We also 
considered cross-sectional studies (CSS) but present them separately because of their descriptive nature 
due to the inability to clearly establish the temporal sequence between SB and biomarkers.   
 
Participants and population 
We selected studies, with the above mentioned characteristics that included older adults (mean age      
≥ 60 years) conducted in the community.  
When we encountered studies with a large age range and a mean age below 60 years, indicating the 
study included some older adults (> 60 years), we attempted to contact the authors to acquire the 
variables of interest for all participants with an age of 60 years and older. Populations with specific co-
morbidity (e.g. diabetes mellitus type 2 (DM-II), peripheral artery disease (PAD), chronic obstructive 
pulmonary disease (COPD) were included, but critically evaluated and highlighted as such. 
 
Data extraction 
All results of the searches were inserted in a bibliographic database. A data extraction form was created 
and amended to the requirements of the review. Two authors piloted (KW; SB) the data extraction form 
in a random sample of 3 studies that employ different study designs. This ensured that the relevant 
information was selected to assess the effectiveness and study quality.  
All data were extracted by these two reviewers. Data extraction included: first author, country, setting, 
population, aims of the study, type of the study (RCT, POS or CSS), number of studies and participants 
included in the article, details of the intervention (including duration), inclusion criteria, type of 
recruitment, type and definition of SB or PA used, biomarkers analysed and results, details of control 
condition, overall study quality (internal risk of bias), association statistics, acknowledged limitations by 
authors, the authors’ conclusions and other notes.   
Any disagreements in data extraction were resolved through discussion between the reviewers.  
Risk of bias and quality assessment 
Assessment of studies followed the PRISMA22 guidelines. Two authors conducted the methodological 
quality appraisal of all included studies using a modified Critical Appraisal Skills Programme (CASP) tool, 
adapted for each study design25:  
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 RCTs (max. CASP score = 6) were assessed for risk of bias in the following domains: clearly 
focused issue, randomization, performance (blinding, personnel), comparability (treatment, 
groups at baseline) and attrition (participants accounted for at its conclusion). 
 POS (max. CASP score = 8) were assessed for risk of bias in the following domains: clearly 
focused issue, selection and recruitment (random approach or representative for a defined 
population, accuracy of measurement (exposure, outcome), identification of important 
confounding factors, adjustment for confounding factors and follow-up (period, completion). 
 CCS (max. CASP score = 6) were assessed for risk of bias in: clearly focused issue, selection and 
recruitment (random approach or representative for defined population), accuracy of 
measurement (exposure, outcome), identification of important confounding factors and 
adjustment for confounding factors. 
In an attempt to assess the potential effect and direction of the effect of SB on specific biomarkers, 
additional information related to statistical evidence of an association, as adapted from the Canadian 
Agency for Drugs and Technology in Health (CADTH)26, was included in Table 2 for the high quality 
studies. The following decision rules as suggested by CADTH26, were used for standardized statements 
about the statistical significance:  
 0% of studies showed statistically significant results = no evidence for any association 
 1% to 33% of studies showed statistically significant results = generally no evidence for any 
association.  
 34% to 66% of studies showed statistically significant results = mixed evidence for association 
 67% or more studies showed statistically significant results = generally evidence for association 
Due to the few studies of high quality, we decided to apply this method of categorisation, although 
often less than 5 studies with statistically significant results were found. To ensure a minimum level of 
validity, we applied this tool in all biomarkers measured in ≥ 3 studies (RCT and/or POS). 
 
Strategy for data synthesis and subgroup analysis 
We tabulated the single study results and grouped them according to comparable biomarkers. All 
results were stratified with appropriate subgroup analyses, for instance according to exposure type (SB 
and PA separately), type of SB/PA assessment (questionnaire- versus sensor-based), biomarker type and 
study design (RCT and CCT separately). We anticipated conducting a meta-analysis if sufficient 
homogeneity was evident across the study types and outcomes of interest and enough studies could be 
identified in comparable areas.   
page 9 of 42          
 
page 10 of 42          
 
Results 
Results of the literature search 
Our initial searches identified 12,701 hits. After the exclusion at title level, removing of duplicates and 
the matching of results from the two independent reviewers (including removing duplicates), a final list 
of 275 full-text articles was scrutinised. 235 articles were subsequently excluded according to our in- 
and exclusion criteria (full details in figure 1). 3 studies included people with a large age range in their 
sample, yet a mean age below 60 years. Upon 3 attempts to contact the authors, 1 group (Aadahl and 
colleagues27) provided additional data, whilst 2 authors did not respond and were subsequently 
excluded due to age < 60 years (Knight et al.28 and Mohri et al.29). 
After exclusions, 40 studies were considered eligible, however after further revision and evaluation, 
another 14 articles (1 POS, 13 CSS) were excluded (for more details see “risk of bias (quality) appraisal”), 
thus leading to a total of 26 articles (4 RCT, 2 POS and 21 CSS). The study from Cooper at al.30 was 
included as a POS and CSS due to longitudinal and cross-sectional analysis of the data reported by the 
study authors. 
 
Definition of Sedentary Behaviour 
We found a highly heterogeneous definition of SB, which was often misclassified as simply the absence 
of PA and therefor 134 papers were excluded. The most frequent definition of SB was total time spent 
at less than 100 counts per minute using data from an accelerometer5,30–38. Henson et al.39 defined SB in 
a similar way but with smaller epochs of less than 25 counts per 15 seconds. Other authors used the 
same definition of SB as used in this review with less than 1.5 MET31,40,41. Some studies did not define SB 
at all27,42.  
A total of 14 studies (3 RCT, 1 POS, 11 CSS, whereas Cooper et al.30 were included as POS and CSS) 
measured SB with sensors or accelerometers, another 2 CSS31,38 with both, accelerometer and 
questionnaire, while 10 studies measured SB by questionnaires only. Of these 10 questionnaires, 6 
enquired about TV watching time (1 POS, 5 CSS), whilst the remainders included more detailed 
questions about SB (1 RCT, 3 CSS).  
 
Characteristics of included studies 
Randomized controlled trials (RCTs)  
An overview of the RCTs is listed in Table 1a. Overall, a total of 397 participants in the RCTs were 
represented (Intervention Group, (IG): 245; Control Group, (CG): 152). Although SB was evaluated, the 
primary aims of 2 RCTs were to increase PA but not reduce SB. 3 RCTs27,41,43 captured SB objectively with 
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an accelerometer (ActiGraph), whereas Kallings et al.44 evaluated SB with the International Physical 
Activity Questionnaire (IPAQ), which consists of 2 questions on the amount of sitting time in the last 7 
days; one for average weekday and one for average weekend day.  
Intervention was mainly focused on increasing habitual PA. This was triggered through different 
processes: an intervention with pedometer-use plus a weekly visit on an interactive website with the 
aim of increasing PA level by 10 % each week up to 10,000 steps/day41; written PA prescription with the 
aim of increasing PA level to 30 min MVPA per day44; a written PA pack with a self-instructional 
workbook based on a trans-theoretical model of behaviour change42. Only 1 study focused on 
decreasing SB with 4 main aims, such as decreasing daily TV viewing time, substitute sitting with 
standing, break up prolonged sitting time and a maximum of 30 minutes of sitting per episode27.  
 
Prospective observational studies (POS) 
An overview of the POS is listed in Table 1a. In the 2 cohort studies30,45 a total of 846 participants were 
represented. Fung et al.45 used a questionnaire focusing on the number of hours of television watching 
to measure SB in men, whereas Cooper et al.30 used objectively measured SB time by accelerometer 
measurements (ActiGraph).  
 
Cross-sectional studies (CSS) 
A total of 41,816 participants were included across the 21 CSS. The characteristics of these CCS are 
listed in Table 1b. Most of the studies focused on SB and its association to biomarkers (16/21 studies), 
from which 5 focused on TV watching time. 2 other studies investigated both SB and PA as exposure34,36, 
1 study46 calculated sitting time, whereas 2 studies evaluated SB as secondary outcome5,6.  
The majority of the studies used objectively measured time of SB by accelerometer (11/21 studies). 2 
studies evaluated both objectively measured SB and SB measured by questionnaire31,38. 5 studies 
focused on time spent with TV watching and 3 used the following questionnaires: Reaven et al.6 adapted 
a questionnaire from the Health Interview Survey, which measured 17 different leisure time activities in 
the last 2 weeks; Larsen et al.46 measured daily SB by asking about time spent being sedentary on a 
typical weekday; Allison et al.47 evaluated the time spent being sedentary by using the “Typical Week 
Physical Activity Survey” which measures SB in the last 7 days.  
 
Sedentary Behaviour and biomarkers  
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Overview of biomarkers explored in the literature 
Table 2 provides an overview of the associations between SB and each biomarker system including: 
anthropometric parameters, systemic parameters, blood lipids, glycaemic parameters, performance 
biomarkers, inflammatory biomarkers and others.  A total of 63 biomarkers were evaluated (counting 
ratios of different biomarkers separately). Table 3 considers the specific biomarker results within each 
study design. There was insufficient homogenous data to perform a meta-analysis. Therefore, we 
describe the number of studies that explored each biomarker and the summary statistics reporting the 
overall proportion of these studies that found a statistical association. Only the statistically significant 
results from the multivariable analyses are shown. If significant, biomarkers showed evidence for an 
unfavourable association with higher ST. Body mass index (BMI, 9 of 15 of the studies significant), waist 
circumference (WC, more than 8 of 15 of the studies significant), insulin (4 of 8 studies significant) and 
high density lipoprotein (HDL, 6 of 15 studies significant) were examined in a lot of studies and 
demonstrated the most reliable results. For a more detailed description see Table 2 and 3.  
We identified 4 “risk population” studies. 1 POS of Cooper et al.30, performed in diabetes type 2 
patients, showed a (statistically significant) positive correlation for SB with WC, HDL, insulin and HOMA-
IR. The CSS from Cooper et al.40, also performed in diabetes type 2 patients, revealed a positive 
association for SB with WC, too. The study from Lee et al.33, performed in the high risk osteoarthritis 
population showed lower gait speed and lower chair stand rate associated with higher levels of SB. 
There were no statistically significant results for the study of Lynch et al.34 investigating the association 
between SB with BMI, WC and insulin in a breast cancer survivor cohort. 
 
Risk of bias (quality) appraisal 
After revising the 40 articles by CASP criteria25 and general quality criteria (correctness of data 
illustration, selection or reporting bias, misclassification etc.) we excluded 13 CSS for the following 
quality linked issues [CASP score] and 1 POS:  
1) SB was not sufficiently measured: Ewald et al.43 [3 of 6] and Bianchi et al.48 [2 of 6] evaluated 
time spent being sedentary with the Physical Activity Scale for the Elderly (PASE) and Kaino et 
al.49 [2 of 6] used the Japan Arteriosclerosis Longitudinal Study Physical Activity Questionnaire 
(JALSPAQ) which are good instruments to measure PA but weak in calculating SB; Calderon-
Garcia et al.50 [4 of 6] calculated ST by asking “How much do you exercise or strain yourself 
physically in your leisure time?’’, which had poor validity. 
2) Missing information about recruitment or cohort characterstics51; 
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3) SB defined as simply being the opposite of PA, as in Gaba et al.52 [3 of 6] or unclear definition of 
sedentariness (Elkan et al.53 [1 of 6], Belza et al.54 [3 of 6]); 
4) Poor quality of exposure or outcome assessment; e.g. Inoue et al.55 [3 of 6] calculated BMI by 
self- reported weight and height, among other issues;  
5) Missing evaluation or lack of adjustment for important confounding factors (comorbidities, 
medication status etc.), e.g. Li et al.57 [2 of 6], Babaroutsi et al.58 [3 of 6] and others51,53–55; 
6) Evidence of selection bias – like in Knight et al.59 [2 of 6]) who compared a cohort from Day Care 
Centre to a cohort from a bowling club; 
7) Implausible or irreproducible data – e.g. implausible data of sample size and sample origin 
(Azzabou et al.51 [3 of 6]); 
8) Biomarker calculated by self-report, like BMI from self-reported weight and height or SB and 
biomarkers weren’t measured at the same point in time (Scott et al. 201560); 
9) We excluded the POS from Wijndaele et al.56 [3 of 8] because BMI was calculated by self-report 
weight.  
After the exclusion of these studies only 2 articles6,61 with a low CASP-score ≤ 3 remained. The mean 
CASP score of RCTs was 5 out of 6, for cohort studies 5 out of 8 and for CSS 4.5 out of 6. 
 
Relation of SB and biomarkers  
Sedentary behaviour and anthropometric and systemic biomarkers 
Of the 15 studies exploring this biomarker, 9 demonstrated a positive association, including 1 RCT44 and 
1 POS45 study (Table 2, 3), whereas 2 RCTs41,42 didn’t show statistically significance, thus there is mixed 
evidence for the association of SB to BMI. WC was also positively associated with SB in 1 POS30 and 7 
CSS, but were not statistically significant in 4 RCTs. Relationships between SB and both systolic BP (3 of 
11 studies reporting this biomarker found positive association) and diastolic BP (1 out of 10 studies 
found a positive associations) were found, whereas the majority showed non-significant results. Neck 
circumference and fat mass were positively correlated to SB but were investigated in only one RCT. 
There was only limited or no evidence for the other anthropometric biomarkers (see Table 2 and 3).   
 
 
Sedentary behaviour and blood lipids  
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Total cholesterol, HDL, low density lipoprotein (LDL) and triglycerides were the main focus in the 
investigated studies. If statistically significant association was prevalent, it was in an unfavourable 
direction. For total cholesterol positive association was found in 1 RCT44, whereas the 3 RCTs27,41,42 and 1 
POS45 didn’t show any statistically significant association. HDL was statistically significant negatively 
associated with SB in 2 POS30,45 but results in 4 RCTs27,41,42,44 were statistically not significant. Similar 
results were detected for the other blood lipids (see Table 2 and 3). Most RCTs didn’t show statistically 
significant results, hence there is generally no evidence for an association of SB and blood lipids. Results 
linking SB and blood lipids mostly derived from CSS studies and thus should be interpreted accordingly. 
 
Sedentary behaviour and glycaemic biomarkers 
There was some indication found of an unfavourable impact of SB on fasting insulin levels, with 
statistically significant associations in 1 RCT27 and 1 POS.30 However 1 RCT41 and 1 POS45 didn’t show any 
association, which lead to mixed evidence for a possible impact of SB on insulin levels. For HbA1c, only 1 
RCT44 was statistically significant. HOMAR-IR30 and C-peptide45 were positively correlated to SB in 1 POS. 
Glucose levels did not appear to be related to SB in 3 RCTs27,41,44. Initially equivocal results in 2 CSS, with 
1 positive32 and 1 negative association62 were clarified by contacting the author. In both studies SB was 
associated with higher blood glucose levels. The impact of SB on glycaemic biomarkers was limited and 
largely restricted to CSS (Table 2 and 3), precluding definitive conclusion.  
 
SB and muscle or physical performance biomarkers 
Muscle tissue, performance, strength or other performance components were measured in 5 CSS (Bann 
et al.31, Santos et al.36, Sardinha et al.37, Lee et al.33, Larsen et al.46). 4 CSS also evaluated the association 
of SB and some performance biomarkers. Lee et al.33 found a statistically significant negative correlation 
for SB with gait speed and chair stand rate. Santos et al.36 constructed a composite Z-score of 6 
performance biomarkers (6 minute walk test, 8 foot up and go, arm curl, chair stand rate, chair sit and 
reach or back scratch) which association with SB was significant negative, but he did not list the results 
separately. Bann et al.31 and Sardinha et al.37 did not find a significant correlation for SB and 
performance biomarkers.  
 
 
SB and inflammatory biomarkers 
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There was a relative paucity of studies investigating inflammatory biomarkers and SB. CRP was 
investigated most frequently, although restricted to 4 CSS studies and 1 RCT, with only 2 CSS studies 
demonstrating that SB was positively associated with CRP. Only 2 CSS studies investigated IL-6 and SB, 
with 1 CSS finding a positive association. Given the limited number of studies and over reliance on CSS, 
the evidence base is inconclusive concerning the relationship between SB and inflammatory markers.  
  
SB and other biomarkers 
There was a distinct lack of studies investigating renal or bone biomarkers and SB. Only 1 study 
measured Vitamin D status60, but it was considered as too low in quality (see 9) in “Risk of bias 
appraisal”), because different points of time exposure and outcome were measured.   
Leptin, which can be seen as adiposity-associated inflammation marker or regulation marker of hunger 
and fat metabolism, was higher with a higher amount of time spent sedentary (2 of 4 studies significant, 
1 POS). 
We could not identify any study investigating renal, cellular, respiratory, signal transduction or genetic 
biomarkers and SB meeting our inclusion criteria. None of the included studies evaluated the impact of 
SB on biomarkers of the gastrointestinal or peripheral/central nervous system, neither focused on 
steroid or hormone biomarkers.  
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Discussion  
Within our comprehensive systematic review, findings from high quality papers showed mixed evidence 
for the association of SB and biomarkers. When statistically significant results were prominent, SB was 
associated in an unfavourable direction, especially in anthropometric (BMI, WC, neck circumference, fat 
mass), blood lipid (cholesterol, HDL, LDL), glycaemic (HbA1c, insulin, HOMA-IR, C-peptide) and hormonal 
(leptin) biomarkers. However several statistically non-significant study results were detected, many of 
which were of high quality. Some results of lower quality studies may be incidental findings or point to 
the existence of additional confounders, which are unaccounted so far.  
Despite the relative paucity and equivocal nature of SB and biomarkers in older age, studies performed 
in younger cohorts strengthen the hypothesis that SB has harmful effects on biomarker levels. For 
instance, Healy et al.67,68 found an inverse relation of breaks in ST and BMI67 and WC67,68 or Zhou69 
revealed an increased risk for developing Metabolic Syndrome (MES) with higher ST support those 
findings. Fasting insulin levels, another MES risk factor, improved with reducing ST27,30. Similar results 
for glycaemic biomarkers, such as postprandial glucose and insulin levels were detected in other 
RCTs70,71 or CSS72 performed in younger cohorts. Considering results from Krogh-Madsen73, showing a 
decrease in insulin-stimulated muscle activity phosphorylation and decreased peripheral insulin 
sensitivity by reducing daily activity for only 2 weeks, there appears to be a strong connection between 
SB and impaired glucose and insulin metabolism in younger age.  
Our review identified some studies that evaluated the association between change in ST and systemic 
parameters, including blood pressure5,6,63, or heart rate6. Surprisingly and contrary to our expectation 
we identified no association between change of SB with blood pressure in 3 included RCTs41,42,44. 
Investigations in younger cohorts demonstrated a clear trend of significantly improving BP levels by 
reducing ST74 or by breaking up prolonged sitting periods75. Already the advice of increasing PA levels 
seems to have a positive effect coming along with lower BP levels76. Possible explanations for no effects 
in older cohorts could be confounding by antihypertensive medication, increased arterial stiffness or 
reduced heart rate variability77 in older age. Similar effects were detected for blood lipids, with better 
profiles associated to less ST78. As underlying mechanism Hamilton et al.79,80 suggested a poor lipid 
metabolism with inactivity by suppression of skeletal muscle lipoprotein lipase activity. SB has also been 
associated with chronic low-grade inflammation in younger cohorts72,81. When looking in elderly people 
we only identified few, mainly CSS32,39,45,47,66, showing higher levels of CRP, IL-6 and leptin in those with 
less physical activity. Besides missing longitudinal data a higher low-grade inflammation82 in older age 
could distort or reduce the effect size of these outcomes.  
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Over and above preserving autonomy in older age is important in order to maintain independence and 
quality of life. Dunlop et al.14 reported a 46% greater odds of ADL disability for each hour spent 
sedentary. Muscle function83 also appears to be negatively affected by SB suggesting that 
macroscopic/performance15 and microscopic/biochemical parameters83 would change depending on ST. 
The results found for our systematic review were few. Results from Santos et al.36 , who constructed a 
composite Z-score out of different performance biomarkers, suggests a negative association for 
performance biomarkers with SB, but no longitudinal data of performance or muscle biomarkers is 
available and thus drawing of causal conclusions is not possible. Given this, future prospective studies 
should prioritise functional assessments like the short physical performance battery (SPPB), grip 
strength and dynamic muscle function. Such measures are easy to ascertain with an evaluated 
predictive profile and can serve as modifiable surrogates of autonomy in later life.  
The highlighted results of the four “risk population” studies showed associations for SB with biomarkers 
in the same direction as the studies performed in non-risk populations. The results from Lee et al.33, 
performed in the high risk osteoarthritis population with lower gait speed and lower chair stand rate 
associated with higher levels of SB can be argued over. This is the only study, which showed (remaining) 
statistically significant results for performance parameters. Even if SB measurements were adjusted for 
osteoarthritis pain index, osteoarthritis symptoms and other comorbidity indices, there could be still 
another unknown confounder, related to osteoarthritis triggering this biomarker outcome.  
Surprisingly, there was an absence of studies (meeting our inclusion criteria) investigating SB and its 
possible impact on renal, muscle or bone biomarkers performed in the elderly. There is however good 
reason to believe that especially bone and muscle metabolism is influenced from SB due to 
multifactorial processes. Prioreschi et al.84 results from a smaller cohort revealed low bone mass for 
higher levels of SB and a possible protective effect for bone mineral density with breaking up ST more 
frequently. Even in younger cohorts, ST has been implicated as being negatively related to changes in 
whole-body bone mineral density, lumbar spine bone mineral content, lumbar spine bone area and 
femoral neck85. 
A large number of studies were excluded from our review because they specifically measured PA rather 
than focus on the distinct construct of SB. For instance, several studies focussed on a lack of PA rather 
than SB42,44. Recently there is a rising interest of SB consequences and the idea of clearly differentiating 
between the distinct behaviours of SB and PA. In this direction, Gibbs et al.86 demonstrated a higher 
effectiveness for improving the SPPB score by reducing SB compared to increasing moderate to vigorous 
PA. For that reason, biomarkers should be evaluated for both, PA and SB. Former investigations have 
shown that SB effects on biomarkers are independently of MVPA levels40,68,72. Additionally reducing 
inactivity often has a higher effectiveness on the biomarker level, than the amount of physical activity 
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itself70,71. For that reason new studies should investigate biomarkers and health outcomes with focusing 
on reducing SB.  
Whilst our comprehensive review provides novel insights, some limitations should be mentioned.  First, 
we identified relatively few high quality or longitudinal studies investigating SB and biomarkers 
specifically in older adults. Therefore, we were not able to conduct a meta-analysis as we anticipated. 
Additionally the CADTH tool26, used for standardized statements about the statistical significance, was 
adapted, so we were able to apply it to fewer studies available. This should be considered, when rating 
the state of evidence. Second, there were no stratified analyses assessing the question if age or gender 
is a possible effect modifier. Both, age and gender were often added into the analysis as confounders, 
but there is still the necessity to evaluate the possible presence of interaction in the association 
between sedentary behaviour and different biomarkers. Third there was considerable heterogeneity in 
the definitions of SB and the high diversity of reported outcome-parameters, again a pertinent factor 
making meta-analysis impossible. SB was often misclassified as simply a lack of PA. With respect to the 
performed analyses some studies measured the mean change31,44, others calculated odds ratios64 or 
Pearson correlation coefficients5, whereas others calculated a linear or multiple regression 
coefficient39,40,47. Strict definitions focussing specifically on SB are necessary to allow comparison of 
results from different studies. There are currently several initiatives attempting to harmonize these 
approaches such as the standardised definition of SB published in 201210, the 2011 launched online 
“Sedentary Behaviour Research Network” (SBRN)87 or the SIT project from Skelton and Chastin88. There 
are some initiatives aimed tackling SB. A large Canadian organization called ParticipACTION89 is trying to 
help Canadians to sit less by offering age adjusted activity programs. Similar intentions are given in the 
multi-centre EU study SITLESS90 with the aim of reducing SB in elderly by a PA intervention enhanced by 
self-management-strategies. Objectively measured SB will be correlated with several biomarkers and 
muscle biopsy results to further elucidate the biochemical influence of SB on health outcomes.  
Currently, we have limited understanding of the impact of SB on different biomarker systems in older 
age. The current knowledge base in this regard is overwhelmingly based upon CSS. Given our findings, 
there is an urgent need for adequately representative, prospective cohort and randomized controlled 
studies to investigate the impact of SB on various biomarkers in order to ascertain a better 
understanding of the pathophysiological and also to test the hypothesis for causality. Besides the 
majority of studies were of moderate to high quality, the presence of reporting bias should still be 
considered. Some effects of selection bias could be present as well, regarding that some studies focused 
on participants of a high risk population, such as diabetes mellitus patients30,40 or breast cancer 
survivors34. Additionally 17 of our 26 studies calculated SB by subjective methods, which are less 
accurate than objective methods, since people tend to underestimate their time spend in SB, due to 
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simple uncertainty or social desirability91. In future research objectively measured SB should be 
preferred to better calculate the real time spent sedentary.  
Conclusion 
There is a paucity of studies investigating the impact of sedentariness in older people. Currently there is 
mixed evidence for the impact of SB and biomarkers. When statistically significant results were found, 
SB was associated in an unfavourable way to biomarkers, but results were mostly derived from cross 
sectional studies and thus should be interpreted accordingly. Due to a broad definition and 
misclassification of sedentary behaviour as simple lack of physical activity there is still a deficiency of 
evident, causal relations. There is a need for high quality studies to better understand the underlying 
pathophysiological pathways and finally the burden between sedentary behaviour and the biomarkers 
implicated. Broad investigations are necessary to evaluate possible impact of sedentary behaviour on 
biomarkers, including those with an absence of data such as bone and muscles biomarkers. Future 
research should utilise an official definition of sedentary behaviour, clearly disentangle the relationships 
between each biomarker and sedentary behaviour and physical activity and use objective or at the least 
use standardised self-report measures for assessing sedentary time. 
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Figure 1 - Flow chart for article selection of randomized controlled trials (RCT), prospective 
observational studies (POS) and cross-sectional studies (CSS) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Remark: One study of Cooper et al.30 was a cohort study with prospective data as well as cross sectional data and thus  
                counted as POS and CS
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Records screened for title and abstract: 
 n = 12701 
Articles screened on full-text: 
n = 275 
Full-text articles excluded because of:  
 not measuring sedentary behaviour:  
n = 134 
 mean age < 60 years: n = 72 
 sample size < 50 people: n = 10 
 article design (review, etc.): n = 8 
 no biomarker: n = 5 
 accelerometer use < 3 days: n = 1 
 no full-text available: n = 2 
 Sedentary behaviour as outcome: n = 1 
 Sedentary behaviour and biomarker not 
correlated: n = 2 
Studies included in final assessment:      
Total:  n = 40*                                               
RCTs:  n = 4                                                   
 POS:  n = 3*                                                 
CSS:  n = 34* 
Studies included in final report: 
 Total:  n = 26* 
 RCTs:  n = 4 
 POS:  n = 2* 
 CSS:  n = 21* 
Excluded papers by titles 
or abstract and duplicate 
records:                                                                                                                  
n = 12426 
Records identified in 
EBSCO database:      
n = 1762 
 
Excluded studies because of lack 
of quality (CASP criteria): 
 RCT:  n = 0 
 POS:  n = 1 
 CSS:  n = 13 
 
n = 8 
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Table 1a - Descriptive overview of randomized controlled trials (RCTs) and prospective observational studies (POS) 
AD = abdominal diameter; Apo = Apo lipoprotein; BF% = percent of body fat; BMI= body mass index ; BP = blood pressure; CD = community-dwelling; CG = control group; CMRF = cardio-metabolic risk factors;                       
CRP = C-reactive protein; DM-II = diabetes mellitus type 2; HbA1c = glycated hemoglobin; HDL = high density lipoprotein; HOMA-IR = homeostatic model assessment of insulin resistance; HOMA%B = homeostatic 
model assessment of B-cell function; HR = heart rate; IG = intervention group; MET = metabolic equivalent; LDL = low density lipoprotein; Lp(a) = lipoprotein a; NC = neck circumference; nr = not reported; s/d BP = 
systolic/diastolic blood pressure; PAS = physical activity scale; POS = prospective observational studies; QUICKI = quantitative insulin sensitivity check index; RCT = randomized  controlled trials; RP = risk population; 
WC= waist circumference  
 
 
Author, Year, 
Country 
Setting, country, study 
Follow-
up 
No. of 
participants 
male 
Age, mean 
±SD [years] 
sedentary behavior 
assessment (method: 
measure) 
measured biomarkers 
CASP 
score 
remarks 
RCTs 
Kallings et al.44 
(2009), Sweden 
CD, “Move study“, 
efficacy of PA on 
prescription to reduce 
CMRF 
6 months 
CG: 54      
IG: 47 
43% 
43% 
all 68 years 
IPAQ questionnaire: 
total sitting time in 
hours/day 
BMI, WC, AD, NC, BF%, fat mass, BF% in 
trunk, fat mass in trunk, glucose,  HbA1c, 
s/d BP, cholesterol, HDL, LDL, LDL/HDL, 
triglycerides, ApoA1, ApoB, ApoB/ApoA1 
5 of 6  
Kirk et al.42   
(2009), UK 
CD + RP,“Time2Act 
study“ in DM-II patients, 
compare 2 methods of 
PA promotion to  
standard care 
6 & 12 
months 
CG: 35    
IG1: 47   
IG2: 52 
51% 
53% 
42% 
59.2±10.4 
60.9±9.6 
63.2±10.6 
ActiGraph GT1M (waist) for 7 
days (≥10 h/d and ≥4days), 
SB not defined 
BMI, WC, s/d BP, cholesterol, HDL, HbA1c 4 of 6 
Groups were not equally 
balanced 
 
Suboc et al.41 
(2014), USA 
CD, investigate if 
reduction of SB 
improves vascular 
endothelial function and 
specific biomarkers 
12 weeks 
CG: 35 
IG1: 32   
IG2: 29 
76% 
61% 
60% 
62±7 
64±7 
63±8 
 
ActiGraph GT3X for 7 days,  
(≥600 min/d and ≥4 days): 
SB defined as ≤ 1.5 METS or 
<100 counts/min 
BMI, WC, glucose, insulin, QUICKI, HOMA-
IR, cholesterol, HDL, LDL, triglycerides, CRP, 
s/d BP, HR, brachial artery diameter,  peak 
shear,  hyperemic peak shear,  
Nitroglycerin mediated dilation, carotid-
femoral pulse wave velocity, augmentation 
index, aortic s/d BP 
6 of 6  
Aadahl et al.27 
(2014), Denmark 
CD, Health2010 study, 
effect of motivational 
counseling at reducing 
sitting time 
6 months 
total: 66 
CG: 28       
IG: 38    
nr 
63 
IG: 64.1 
CG: 63.8 
ActivPAL 3TM (triaxial, right 
thigh) for 7 days (at least 2 
days for analysis), SB not 
defined 
WC, BF%, glucose, insulin, HbA1c, 
cholesterol, HDL, LDL, triglycerides 
5 of 6 
Only 2 days of 
accelerometer but 94 %  
of total group n=166 had 
5days or more; special 
sub-analysis for us with 
people > 60 years; 
POS 
Fung et al.45 
(2000), USA 
CD, “Health 
Professionals Follow-up 
Study”, television 
watching and 
biomarkers 
1986-
1994 
466 100% 60 
Questionnaire: hours of 
television watching/week 
 
BMI, cholesterol, HDL, LDL, triglycerides, 
ApoA1, Lp(a), Leptin Fibrinogen, Insulin, C-
peptide, HbA1c 
5  of 8 
Biomarker only at 
follow-up  no change 
available 
Cooper et al.30 
(2012), UK 
CD + RP, “Early ACTivity 
in Diabetes study”, with 
DM-II patients, RCT but 
results treated as a 
cohort 
6 months 
528 cross 
sectional; 
380 
longitudinal 
data 
65% 59.810.0 
ActiGraph GT1M (waist) for 
7 days (≥600 min/d and ≥ 3 
valid days) removed for 
sleeping; non-wear time ≥ 
20 min with 0 counts, SB 
(h/day) defined as < 100 
counts/minute 
WC, HbA1c, HDL, glucose, insulin, HOMA-IR 5 of 8  
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Table 1b - Descriptive overview of 21 cross-sectional studies (CSS) 
 
Author, year, 
country 
Setting, study, aim 
No. of 
participant
s 
Male 
(%) 
Age, mean 
(±SD/range) 
[years] 
Sedentary behavior (SB) assessment 
(method: measure) 
Analyzed  biomarkers 
CASP 
score 
Remarks 
Allison et al.47 
(2012), USA 
CD, Multi-Ethnic Study of 
Atherosclerosis (MESA),  
association of SB with adiposity 
associated measures of 
inflammation 
1543 49.8 
64.3 (9.6) (45-
84) 
Questionnaire “Typical Week Physical 
Activity Survey” (TWPAS), which measures 
also SB (TV, computer, reading) (min/week: 
continuous and in tertiles) during a typical 
week 
adiponectin, leptin, TNF-a, 
resistin, adiponectin/leptin 
4 of 6 
Multivariate adjusted means and 
coefficients of multivariate linear regression 
models, three models with different level of 
adjustment; 
Anuradha et al.65 
(2011), USA3 
CD, Multi-Ethnic Study of 
Atherosclerosis (MESA), 
association of TV watching time 
and retinal vascular caliber 
5893 48 
63.1 (9.9) (45-
84) 
Questionnaire about TV watching  time 
(quartiles: hours/week) during a typical 
week 
central retinal artery 
equivalent, central retinal vein 
equivalent 
4 of 6 
Least square means of multivariate linear 
regression models, two models with 
different level of adjustment 
Bankoski et al.62 
(2011), USA 
CD, National Examination Survey 
(NHANES); association between 
SB and MES 
1367 51.8 71 (7.8) (≥60) 
ActiGraph AM-7164 (uniaxial, waist) for 7 
days (≥ 4 valid days) removed for bathing 
and sleeping; non-wear time > 60 min with 
0 counts; SB (hours/day) defined as < 100 
counts/minute 
dichotomized: WC, HDL, 
triglycerides, glucose, BP 
5 of 6 Means adjusted for age and sex 
Bann et al.31    
(2015), USA 
CD, Lifestyle Interventions and 
Independence for Elders (LIFE) 
Study, association of SB with 
BMI and grip strength 
1130 33 
NR (70-89) 
m: 79.3 (5.3) 
w: 78.5 (5.3) 
ActiGraph GT3X (triaxial, waist) for 7 days 
(≥600 min/d and ≥3 valid days) removed for 
bathing and sleeping; non-wear time ≥90 
min with 0 counts; SB (min/day) defined as 
< 100 counts/minute                                          
CHAMPS questionnaire about a typical 
week; SB (min/day) was defined as time 
≤1.5 METs 
BMI, grip strength 4 of 6 
Coefficients of multivariate linear regression 
models, two models with different level of 
adjustment; no numbers regarding men and 
women although all analyses were stratified 
according to sex 
Cooper et al.30 
(2012), UK 
RP (type 2 diabetes), Early 
Activity in Diabetes (Early-
ACTID), association between SB 
& CMRF 
528 
m: 344 
w: 184 
65 
59.8 (10) (30-
80) 
m: 60.7 (9.7) 
w: 58.1 (10.4) 
ActiGraph GT1M (waist) for 7 days (≥600 
min/d and ≥ 3 valid days) removed for 
bathing and sleeping; non-wear time ≥ 20 
min with 0 counts, SB (h/day) defined as < 
100 counts/minute 
WC, HDL, insulin, HOMA-IR 5 of 6 
Subsample in POS table 
Coefficients of multivariate linear 
regressions 
Cooper et al.40 
(2014), UK 
RP (type 2 diabetes), ADDITION-
Plus Study, associations of SB 
and PA with metabolic risk 
394 
m: 250 
w: 144 
63 
60.3 (7.4) 
m: 60.2 (7.4) 
w: 60.5 (7.4) 
Actiheart for 4 days; SB was defined as 
activity < 1.5 MET 
WC, systolic BP, HbA1c, 
triglycerides, HDL 
6 of 6 
Coefficients of multivariate linear regression 
models, three models with different level of 
adjustment; adjusted to possible 
confounders, limitations mentioned; 
difficult to distinguish between sitting and 
standing by using Actiheart 
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Jakes et al.63    
(2003), UK 
CD, European Prospective 
Investigation into Cancer (EPIC) 
study, association between TV 
watching and vigorous activity 
with obesity and CVD risk profile 
14189 42 
60.3 (45-74) 
m: 61(9) 
w: 59.9 (8.9) 
Self-reported TV watching time (four 
groups: hours/day), separated for weekday 
and weekend day, 
BMI, WC, HC, WHR, BF%, s/d 
BP, HbA1c, triglycerides, 
cholesterol, HDL, LDL 
4 of 6 
Means adjusted for age and multivariate 
adjusted; rational for grouping of TV 
watching is unclear, numbers per group are 
not given 
Gabriel et al.5 
(2013), USA 
CD, Healthy Women Study 
(HWS), association of PA with 
coronary artery calcification 
progression 
148 0 73.2 (1.7) 
ActiGraph GT1M (uni-axial, waist) for 7 days 
for 24h (≥600min/d and ≥4 days); non-wear 
time ≥ 60 min with 0 counts; SB (min/day) 
was defined as <100 counts per minute 
BMI, WC, s/d BP, cholesterol, 
LDL, HDL, triglycerides, 
glucose, insulin 
5 of 6 
Correlation coefficients between SB and 
biomarkers; different methods used during 
different FU state 
 
Gao et al.64       
(2007), USA 
CD, association of TV watching 
time and prevalence of MES 
455 40 68.8 (≥60) 
Self-reported TV watching time (quartiles: 
hours/day) 
BMI, dichotomized: WC, 
triglycerides, HDL, BP, glucose, 
cholesterol/HDL, WHR 
5 of 6 
Means for BMI, proportions and 
multivariate adjusted ORs for all 
dichotomized variables; only Hispanics with 
Puerto Rican or Dominican origin; 
Gardiner et al.21 
(2011), Australia 
CD, Australian Diabetes, Obesity 
and Lifestyle (AusDiab) study, 
relation between TV watching 
and sitting time with MES 
1958 46 
69 (≥60) 
m: 69.6 
w: 69 
Questionnaire about TV and sitting time 
(quartiles: hours/day) 
Dichotomized: WC, 
triglycerides, HDL, BP, glucose 
4 of 6 
OR from multivariate adjusted models; TV 
time and sitting time measured separately. 
Discrepancy in numbers, given in the paper, 
detected: Females: No MES (n=643) and 
MES (n=460) -> n=1103 does not match 
total number of 1062; 
Genusso et al.32 
(2013), USA 
CD, National Examination Survey 
(NHANES) subsample, 
association between SB and 
CMRF 
1914 52 
74.6 (6.5) 
(≥65) 
ActiGraph  AM-7164 (uniaxial, waist) for 7 
days (≥600 min/day and ≥1 valid day) 
removed for bathing and sleeping; non-
wear time ≥ 60 min with 0 counts; SB 
(quartiles: hours/day) defined as < 100 
counts/minute 
BMI, WC, s/d BP, cholesterol, 
HDL, triglycerides, LDL, 
glucose, HbA1c, CRP 
5 of 6 
Least square means multivariate adjusted; 1 
day enough for getting included in analysis; 
analysis of triglycerides, LDL and glucose 
only on subsample of 809 people – we 
already excluded papers because of accel. 
only 1 day 
Hamer et al.66 
(2013), UK 
CD, English Longitudinal Study of 
Ageing (ELSA), association 
between TV watching time. CRP 
and depressive symptoms 
4964 45.1 64.5 (8.9) 
Questionnaire about TV watching time on 5 
weekdays and weekend separately (4 
groups: hours/day) 
 
CRP 
 
4 of 6 
Mean change in relation to a reference 
group, two models with different level of 
adjustment 
Henson et al.39 
(2013), UK 
CD, „Walking Away from Type 2 
Diabetes study”, association 
between SB and inflammation 
and adiposity 
558 65 63.6 (7.7) 
ActiGraph GT3X (tri axial) for 7 days (≥600 
min/d and ≥ 4 valid days); non-wear time ≥ 
60 min with 0 counts; SB 
(hours/day)defined as <25 counts/15 sec; 
CRP, leptin, IL-6, adiponectin, 
leptin/adiponectin 
5 of 6 
Coefficients of multivariate linear regression 
models, three models with different level of 
adjustment; not mentioned where 
accelerometer got attached to; 
Larsen et al.46 
(2014), USA 
CD, Rancho Bernardo Study 
(RBS); associations of sitting 
time with regional fat and 
abdominal muscle 
539 
m: 135 
w: 404 
25 
64.6 (7.4) 
(≥55) 
Single item about time spent in leisure time 
sitting activities on a typical weekday 
(tertiles: hours/day) 
BMI, TNF-a, adiponectin, 
leptin, IL-6, HDL, LDL, 
triglycerides; pericardial-, 
intra-thoracic-,visceral-, 
intermuscular- and 
subcutaneous fat, abdominal 
and psoas muscle 
4 of 6 
Unadjusted means; low sensitivity with 
measuring SB by a single self-report item for 
1 day 
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Lee et al.33      
(2015), USA 
RP (adults with or at high risk for 
knee osteoarthritis), 
osteoarthritis initiative (OAI), 
association between SB and 
physical function 
1168 45 66 (45-79) 
ActiGraph GT1M (uniaxial, waist) for 7 days 
(≥600 min/d and ≥4 days) removed for 
bathing and sleeping; non-wear time by ≥ 
90 min with 0 counts; SB (quartiles: % of 
day) was defined as <100 counts per min 
BMI (3 categories), gait speed, 
chair stand rate 
5 of 6 
Unadjusted means for BMI and multivariate 
adjusted mean differences between 
categories of SB; adjusted to confounders 
but only  arthritis patients 
Lynch et al.34   
(2010), USA 
RP (breast cancer survivors), 
National Examination Survey 
(NHANES), association of PA and 
SB with adiposity 
111 0 69.2 (13) 
ActiGraph 7164 (uniaxial, waist) for 7 days 
(≥600 min/d) removed for bathing and 
sleeping; non-wear time ≥60 min with 0 
counts; SB (hours/day) was defined as  < 
100 counts/min; 
BMI, WC, insulin 5 of 6 
Coefficients of multivariate linear regression 
models, three models with different level of 
adjustment; due to missing values the 
number of subjects varied (BMI: 106, WC: 
100, insulin: 35); not mentioned how many 
days of accelerometer were necessary to 
get included in study 
Lynch et al.35   
(2011), USA 
CD, postmenopausal women of 
National Examination Survey 
(NHANES), 
1024 0 63.0 (9.4) 
ActiGraph 7164 (uniaxial, waist) for 7 days 
(≥600 min/d) removed for bathing and 
sleeping; non-wear time ≥60 min with 0 
counts; SB (hours/day) was defined as  < 
100 counts/min; 
BMI, WC, CRP, fasting glucose, 
insulin, HOMA-IR 
5 of 6 
Coefficients of multivariate linear regression 
models, three models with different level of 
adjustment; data not following normal 
distribution were transformed by natural 
logarithm 
Reaven et al.6 
(1991), USA 
CD, relation between leisure 
time PA and BP 
641 0 66.5 (50-89) 
Questionnaire adapted from Health 
Interview Survey with 17 leisure time 
activities, (2 weeks) 
HR, BMI, s/d BP, fasting 
insulin, 2h insulin 
3 of 6 
Means adjusted for age (all), means 
multivariate adjusted (s/d BP) 
Santos et al.36 
(2012), Portugal 
CD, association of PA and SB 
with functional fitness 
312 
m: 117 
w: 195 
37.5 
74.3(6.6) 
(≥65) 
m: 74.2 (6.2) 
w: 74.3(6.9) 
ActiGraph, GT1M (waist) for 4 days (2 
weekdays and 2 weekend days) (≥ 10h/d 
and ≥ 3 days with ≥ 1 weekend day); non-
wear time ≥ 60 min 0 counts; SB (min/day) 
was defined as <100 counts per minute 
Chair stand repetitions, arm 
curl, 6MWT, 8 foot up and go, 
chair sit and reach, back 
scratch 
4 of 6 
Coefficients of multivariate linear regression 
models, four models with different level of 
adjustment; nothing said about exclusion 
criteria, not mentioned if it was performed 
in the same center of same examiners,  not 
medication or comorbidities got evaluated 
Sardinha et al.37 
(2015), Portugal 
CD, association of SB with 
physical function 
215 
m: 87 
w: 128 
40 
73.3 (5.9) (65-
94) 
m: 73.7 (6.2) 
w: 73.0 (5.7) 
ActiGraph, GT1M (waist) for 4 days (2 
weekdays and 2 weekend days) (≥ 10h/d 
and ≥ 3 days with ≥1 weekend day); non-
wear time ≥ 60 min 0 counts; SB (min/day) 
was defined as <100 counts per minute 
6MWT, 8 foot up and go, arm 
curl, chair stand, chair sit and 
reach, back scratch 
6 of 6 Good adjustment for possible confounders 
Stamatakis et al.38 
(2011), UK 
CD, Health Survey for England 
(HSE), association between SB 
and CMRF 
2765 with 
self-report;            
649 with 
acceleromet
er 
45 70 (≥60) 
ActiGraph GT1M for 7 days (≥600 min/d 
and ≥ 1 valid day), non-wear time ≥ 60 min 
with 0 count, SB (tertiles: min/day) defined 
as < 100 counts/minute; self-reported 
leisure-time SB (tertiles: min/day) 
BMI, WC, cholesterol, HDL, 
HbA1c, cholesterol/HDL ratio 
5 of 6 
Unadjusted means; 1 valid day included in 
analysis, but 91% had > 5 days; different 
sample sizes of accelerometer measured 
and self-report sample (sensitivity analysis 
showed that this difference might 
contribute to differential associations; 
sample for blood biomarker was 
considerably smaller (1354/333) 
6MWT = 6 meter walk test; ABI = ankle brachial index; AD = abdominal diameter; Apo = Apo lipoprotein; BP = blood pressure; BF% = percent of body fat; BFMI = body fat mass index (kg/m2); BMD = bone mineral 
density; BMI= body mass index; CCS = cross-sectional study; CD = community-dwelling; CG = control group; CMRF = cardio-metabolic risk factors; CRP = C-reactive protein; CV = cardiovascular; CVBM = 
cardiovascular biomarker; CVD = cardiovascular disease; DM-II = diabetes mellitus type 2; FEV1 = forced expiratory volume within 1 second; FFMI = fat free mass index (kg/m2); FVC = forced vital capacity; HC = 
hip circumference ;HDL = high density lipoprotein; HOMA-IR = homeostatic model assessment of insulin resistance; HOMA%B = homeostatic model assessment of B-cell function; HR = heart rate; IG = intervention 
group; IL-6 = interleukin 6; LDL = low density lipoprotein; MES = metabolic syndrome; MET = metabolic equivalent; NC = neck circumference; NHANES = National Health and Nutrition Examination Survey;  NR = 
not reported; OR = odds ratio; PA = physical activity; PAD = peripheral artery disease; PAI = plasminogen activator inhibitor 1; PAL = physical activity level; PAS = physical activity scale; PASE = physical activity scale 
for the elderly; RCT = randomized  controlled trials; RP = “risk population” defined as population with specific illness such as diabetes or peripheral artery disease; s/d = systolic/diastolic; SB = sedentary behavior; t-
PA = tissue plasminogen activator; TNF-a = tumor necrosis factor a; WC= waist circumference; WHR = waist to hip ratio  
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Table 2 – Overview of biomarkers evaluated in the systematic review articles 
 Study results  
Interpretation of the statistical significance level in 
high quality papers, adapted from CADTH26 
Category of 
biomarker 
Biomarker type 
Number of 
studies by 
study type                
(RCT/ POS/CSS) 
Statistically not 
significant 
studies (n) 
p<0.05 in 
un-
adjusted 
results (n)  
p<0.05 fully adjusted                 
(n, study type, direction of    
association +/-) 
High quality 
studies (n); 
participants (n) 
Results  
(%) 
Interpretation 
Anthropo-
metric 
parameters 
BMI 3/1/11 
5 (2 RCT42,41,              
3 CSS46,33,64) 
10 
9 (1 RCT+44, 1 POS+45,                                       
7 CSS+32,63,6,31,5,38,35)                                                                 
4 studies;                  
797 participants  
50 % 
significant 
Mixed evidence for 
association 
WC 4/1/10 
5 (4 RCT42,41,27,44,       
1 CSS,64) 
10 8 (1 POS+30, 7 CSS+5, 32, 63,35, 62, 40,38) 
5 studies;                  
777 participants 
20 % 
significant 
Generally no evidence 
for association  
HC 0/0/1 0 1 1 CSS+63 Not applicable  
WHR 0/0/2 0 2 2 CSS+64,63 Not applicable 
neck circumference 1/0/0 0 1 1 RCT+44 Not applicable 
abdominal diameter 1/0/0 1 RCT44 0 0  Not applicable 
BF% 2/0/1 2 RCT27,44 1  1 CSS+63 Not applicable 
fat mass 1/0/0 0 1 1 RCT+44 Not applicable 
BF in trunk 1/0/0 1 RCT44 0 0  Not applicable 
fat mass in trunk 1/0/0 1 RCT44 0 0 Not applicable 
pericardial fat 0/0/1 0 1 1 CSS+46 Not applicable 
intra-thoracic fat 0/0/1 0 1 0  Not applicable 
visceral fat 0/0/1 0 1 0 Not applicable 
intermuscular fat 0/0/1 0 1 0 Not applicable 
subcutaneous fat 0/0/1 0 1 0 Not applicable 
abdominal muscle 0/0/1 1 CSS46 0 0 Not applicable 
psoas muscle 0/0/1 1 CSS46 0 0 Not applicable 
Systemic 
parameters 
systolic BP 3/0/8 
7 (3 RCT44,42,41,           
4 CSS32, 40,62,21) 
4 3 CSS+63,6,5 
3 studies;                 
331 participants 
0 % 
significant 
No evidence for 
association 
diastolic BP 3/0/7 
7 (3 RCT44,42,41,          
4 CSS32,5,62,21) 
3 1 CSS+63 
3 studies;                 
331 participants 
0 % 
significant 
No evidence for 
association 
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HR 1/0/1 1 RCT41 1 1 CSS+6                                                                                            Not applicable 
brachial artery diameter 1/0/0 1 RCT41 0 0 Not applicable 
peak shear 1/0/0 1 RCT41 0 0 Not applicable 
hyperemic peak shear 1/0/0 1 RCT41 0 0 Not applicable 
nitroglycerin mediated 
dilation 
1/0/0 1 RCT41 0 0 Not applicable 
carotid-femoral pulse wave 
velocity 
1/0/0 1 RCT41 0 0 Not applicable 
augmentation index 1/0/0 1 RCT41 0 0 Not applicable 
aortic s/d BP 1/0/0 1 RCT41 0 0 Not applicable 
central retinal artery 
equivalent 
0/0/1 1 CSS65 0 0 Not applicable 
central retinal vein equivalent 0/0/1 0 1 1 CSS+65 Not applicable 
Blood lipids 
total cholesterol 4/1/4 
7 (3 RCT27,42,41,          
1 POS45, 3 CSS 32,38,5) 
2 2 (1 RCT+44, 1 CSS+63) Not applicable 
HDL 4/2/9 
7 (4 RCT27,42,41,44,       
3 CSS32,46,5) 
8 6 (2 POS-30,45, 4 CSS-63, 38, 62, 64) 
6 studies;               
1243 participants 
33 % 
significant 
Generally no evidence 
for association 
LDL 3/1/4 
6 (3 RCT27,41,44,           
3 CSS32,46,5) 
2 2 (1 POS+45, 1 CSS+63) 
4 studies;                  
729 participants 
25 % 
significant 
Generally no evidence 
for association 
LDL/HDL 1/0/0 1 RCT44 0 0 Not applicable 
cholesterol/ HDL 0/0/2 0 2 2 CSS+64,38 Not applicable 
triglycerides 3/1/8 
8 (3 RCT27,41,44, 1 
POS45, 4 CSS32,46,5,64) 
4 2 CSS+62,63 
4 studies;                  
729 participants 
0 % 
significant 
No evidence for 
association 
ApoA1 1/1/0 1 RCT44 1  1 POS-45 Not applicable 
ApoB 1/0/0 1 RCT44 0 0 Not applicable 
ApoB/ApoA1 1/0/0 1 RCT44 0 0 Not applicable 
Lp(a) 0/1/0 1 POS45 0 0 Not applicable 
Glycemic 
parameters 
HbA1c 3/1/4 
5 (2 RCT27,42,              
1 POS45, 2 CSS32,40) 
3 2 (1 RCT+44, 1 CSS+38) 
4 studies;                  
767 participants 
25 % 
significant 
Generally no evidence 
for association 
glucose 3/0/6 
6 (3 RCT27,41,44,           
3 CSS35,5,64) 
3 2 CSS+32,62 
3 studies;                  
263 participants 
0 % 
significant 
No evidence for 
significant association 
insulin (fasting) 2/2/4 2 (1 RCT41, 1 POS45) 6 4 (1 RCT+27, 1 POS+30, 2 CSS+5,6) 
4 studies;                
1008 participants 
50 %  
Mixed evidence for 
association 
insulin (after 2h) 0/0/1 0 1 1 CSS-6 Not applicable 
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HOMA-IR 1/1/1 1 RCT41 2 1 POS+30 Not applicable 
QUICKI 1/0/0 1 RCT41 0 0 Not applicable 
C-peptide 0/1/0 0 1 1 POS+45 Not applicable 
Performance 
biomarkers 
6MWT 0/0/2 2 (1 CSS37, NR*36) 0 0 Not applicable 
8 foot up and go 0/0/2 2 (1 CSS37, NR*36) 0 0 Not applicable 
grip strength 0/0/1 1 CSS31 0 0 Not applicable 
gait speed 0/0/1 0 1 1 CSS-33 Not applicable 
arm curl 0/0/2 NR*36 1 0 Not applicable 
Chair stand rate 0/0/3 NR*36 2 1 CSS-33 Not applicable 
Chair sit and reach 0/0/2 NR*36 1 0 Not applicable 
Back scratch 0/0/2 1 (CSS37, NR*36) 0 0 Not applicable 
Inflammatory 
biomarkers 
CRP 1/0/4 1 RCT41 4 2 CSS+32,66 Not applicable 
Fibrinogen 0/1/0 1 POS45 0 0 Not applicable 
IL-6 0/0/2 1 CSS46 1 1 CSS+39 Not applicable 
Others 
Leptin 0/1/3 1 CSS46 3 2 (1 POS+45, 1 CSS+47) Not applicable 
Adiponectin 0/0/3 2 CSS47,39 1  1 CSS+46 Not applicable 
leptin / adiponectin ratio 0/0/1 0 1 0 Not applicable 
adiponectin/ leptin ratio 0/0/1 0 1 1 CSS-47 Not applicable 
TNF-a 0/0/2 1 CSS46 1 1 CSS+47   Not applicable                                                                                    
Resistin 0/0/1 1 CSS47 0 0 Not applicable 
Remark: Results from Cooper et al.20 are only listed in POS results, not additionally in CSS column; *Santos et al.36 calculated a composite Z-score, but didn’t report separate associations for each biomarker with SB 
6MWT = 6 meter walk test; adj. = adjusted; Apo = Apo lipoprotein; BF% = percent of body fat; BMI = body  mass index (kg/m2); ; BP = blood pressure; CSS = cross-sectional study; CRP = C-reactive protein; FFMI = fat 
free mass index (kg/m2); HbA1c = specific glycated hemoglobin; HC = hip circumference; HDL = high density lipoprotein; HOMA-IR = homeostatic model assessment of insulin resistance; HR = heart rate; IL = 
interleukin; LDL = low density lipoprotein; Lp(a) = lipoprotein a; NR = not reported; PA = physical activity; POS= prospective observational studies; QUICKI = quantitative insulin sensitivity check test; RCT = randomized  
controlled trials; reg. coeff. = regression coefficient; s/d = systolic/diastolic; sig. = significant; SB = sedentary behaviour; ST = sedentary time; TNF-a = tumor necrosis factor a; unadj. = unadjusted; WC= waist 
circumference; WHR = waist to hip ratio 
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Table 3 - Details of randomized controlled trials (RCTs), prospective observational studies (POS) and cross-sectional studies (CSS) including 
significant associations of biomarkers with Sedentary Behaviour 
 
Author, 
Year 
No. of 
participants 
What was analyzed?                                     
What was measured? 
Measured 
biomarkers 
Main results (95%CI) or [SD] or {SE} P-value 
CASP 
score 
Remarks 
RCTs 
Kallings et 
al.44 (2009) 
CG: 54               
IG: 47 
Significant differences between IG and 
CG  in mean change (MC) of biomarker 
from baseline (B) to follow up (FU); 
reducing SB was measured, thus 
changes are negative  
 
BMI (kg/m2) MC IG: -0.6 (-0.9 to -0.3) vs. MC CG: -0.2 (-0.4 to 0.0) 0.02 
5/6 
MC from B to FU in sitting 
time (hours/day) in CG with 
-1h/d (p <.001) and IG with 
-2h/d (p <.0.01)  
NC (cm) MC IG: -1.2 (-1.6 to -0.8) vs. MC CG: -0.6 (-1.0 to -0.2) 0.01 
Fat mass (kg) MC IG: -1.7 (-2.5 to -0.9) vs. MC CG: -0.6 (-1.2 to -0.1) 0.03 
HbA1c (%) MC IG: -0.1 (-0.2 to 0.0) vs. MC CG: 0.2 (0.1 to 0.3) 0.001 
Cholesterol 
(mmol/l) 
MC IG: -0.3 (-0.6 to 0.0) vs. MC CG: 0.1 (-0.1 to 0.1) 0.04 
Aadahl et 
al.27 (2014) 
Total: 66       
IG: 38         
CG: 28 
Mean difference (MD) in change of 
fasting serum insulin from baseline (B) 
to follow up (FU) between IG and CG 
for reducing SB 
Fasting insulin 
(pmol/l) 
-0.51 (-0,01 to -1.00) 0.04 5/6 
CG means [SD] of sitting 
time in B = 9.8 [2.0] and FU 
= 10.2 [1.9]; IG means [SD] 
of sitting time in B = 9.27 
[1.9] and FU = 8.7 [1.5] 
POS 
Fung et al.45 
(2000) 
466 
Pearson correlation coefficient (PCC) 
of television hours and biomarker; 
linear regression coefficient (lrc) for 
1994 TV hours1 or average TV hours in 
1988-19942 
BMI (kg/m2) PCC: 0.13 <0.01 
5 of 8 
Lrc calculated for 
increment of 14 hours 
television watching per 
week 
Leptin (ng/ml) 
PCC: 0.15                                                                                                        
lrc: 1.3 {0.5}2, adj. to BMI 0.8 {0.4}2 
<0.01; 
<0.01, 
<0.05 
C-peptide (ng/dl) PCC: 0.12 <0.05 
ApoA1 (mg/dl) 
lrc: -5.3 {2.0}1                                                                                                    
adj. to BMI -4.9 {2.0}1 
<0.05
<0.05 
HDL (mg/dl) 
lrc: -3.9 {1.2}1                                                                                                   
adj. to BMI -3.4 {1.2}1 
<0.01
<0.01 
LDL (mg/dl) 
lrc: 6.1 {2.9}1                                                                                                      
adj. to BMI 6.1 {2.9}1 
<0.05  
<0.05 
Cooper et 
al.30 (2012) 
528/380 
Mean change (MC) in biomarker from 
baseline (B) to follow-up; cross-
sectional regression coefficient (csrc) 
for baseline sample (bs)  and 
longitudinal sample (ls) or longitudinal  
linear regression coefficient (llrc); 
additionally adj. to WC3 
WC (cm) 
MC: -1.9 (-2.3 to -1.4)                                                                                       
B csrc: 1.8 (0.9 to 2.8)                                                                                     
ls csrc: 1.8 (0.6 to 2.9) 
<0.001
<0.001
0.002 
5 of 8 
Csrc and llrc calculated for 
ST in hours/day 
HDL (mmol/l) 
bs B csrc: -0.03 (-0.06 to -0.01)                                                                          
bs B csrc3: -0.03 (-0.05 to -0.004)                                                                                                      
ls B csrc: -0.04 (-0.076 to -0.01)                                                                          
ls B csrc3: -0.03 (-0.07 to -0.00)                                                                        
0.005
0.02 
0.006    
0.01         
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ls FU csrc: -0.05 (-0.088 to -0.020)                                                               
ls FU csrc3: -0.05 (-0.08 to -0.01)                                                                 
llrc: -0.04 (-0.08 to -0.01) 
0.002
0.003
0.007 
Insulin (pmol/l) 
MC: -9.4 (-14.4 to -4.4)                                                                                 
bs b csrc: 8.2 (2.8 to 13.6)                                                                              
ls B csrc: 12.0 (5.0 to 19.1)                                                                               
ls B csrc3: 8.5 (1.8 to 15.2)                                                                                
llrc: 8.1 (1.5 to 14.7) 
<0.001
0.003
0.001    
0.01
0.01 
HOMA-IR 
MC: -0.36 (-0.6 to -0.0)                                                                                 
bs B csrc: 0.4 (0.1 to 0.7)                                                                                 
ls B csrc: 0.6 (0.2 to 0.9)                                                                                  
ls B csrc3: 0.4 (0.1 to 0.8)                                                                                
ls llrc: 0.4 (0.0 to 0.9) 
0.03 
0.004
0.001  
0.009
0.02 
CSS 
Allison et 
al.47 (2012) 
1543 
Linear regression coefficient (lrg) 
calculated for natural logarithm of 
biomarker and increment of SB (790 
MET-minutes/week) adj. for 
confounders or additionally to BMI 
and more conf.4, or add. to WC5 
Leptin (ng/ml) 
0.15 (0.10 to 0.20)                                                                                    
0.07 (0.04 to 0.11)4                                                                                    
0.07 (0.03 to 0.10)5 
<0.05   
<0.05
<0.05 
4 of 6  TNF-a (pg/ml) 
0.04 (0.01 to 0.06)                                                                                   
0.03 (0.01 to 0.06)4                                                                                   
0.03 (0.00 to 0.06)5 
<0.05   
<0.05
<0.05 
Adiponectin/             
Leptin ratio 
-0.17 (-0.23 to -0.11)                                                                                     
-0.08 (-0.12 to -0.03)4                                                                                   
0.07 (-0.11 to -0.02)5 
<0.05  
<0.05
<0.05 
Anuradha 
et al.65 
(2011) 
5893 
Multivariate-adjusted mean difference 
for highest compared to lowest 
quartile of TV viewing time (>3 h/d to 
<1 h/d)  
Central retinal vein 
equivalent (µm) 
1.8 (0.4 to 3.2) <0.05 4 of 6  
Bankoski et 
al.62 (2011) 
1367 
Age and sex adjusted means of 
biomarker and MES risk profile 
(according to the ATP III guidelines) for 
duration of ST6 (in hours/day) and % of 
ST of total wear time7 
Large WC* 
no risk 9.2 {0.1}6 to risk  9.6 {0.1}6                                                             
no risk 62.6 {0.4} 7 to risk 66.6 {0.6}7 
0.04
<0.01 
5 of 6  
Low HDL* no risk 64.2 {0.5} 7 to risk 67.7 {0.6}7 <0.01 
High Triglycerides* 
no risk 9.2 {0.1}6 to risk  9.6 {0.1}6                                                            
no risk 63.8 {0.5} 7 to risk 67.0 {0.6}7 
0.05
<0.01 
High glucose no risk 63.6 {0.5} 7 to risk 66.0 {0.6}7 <0.01 
Bann et 
al.31 (2015) 
1130 
Mean differences in BMI per hour/day 
increase in ST measured by 
accelerometer (ACC)8and self-report 
(SR)9 
BMI (kg/m2) 
ACC minimally adj.: 0.42 (0.13 to 0.71)                                                      
ACC fully adj.: 0.44 (0.14 to 0.74)                                                               
SR minimally adj.: 0.37 (0.06 to 0.67)                                                       
SR fully adj.: 0.51 (0.19 to 0.82) 
0.005
0.004
0.01
0.002 
4 of 6  
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Cooper et 
al.40 (2014) 
394 
m: 250 
w: 144 
Linear reg. coeff. for ST and WC, crude, 
adj. to confounders and add. adj. to PA 
WC (cm) 
crude: 0.80 (0.31 to 1.29)                                                                        
adj.: 0.97 (0.46 to 1.48)                                                                           
adj. + PA: 0.68 (0.01 to 1.35) 
<0.05
<0.05
<0.05 
6 of 6 
Linear regression analyses 
performed for ST in 
hours/day 
Jakes et 
al.63    
(2003) 
14189 
Age adjusted mean value of biomarker 
in relation to television viewing h/d 
(<2h, 2-2.9, 3-3.9, >4) in men and 
women, add. adj. to confounders10 
BMI (kg/m2) 
m: 26.1 [3.1], 26.4 [3.0], 26.7 [3.2], 27.1 [3.2]                                       
w: 25.3 [3.9], 26.0 [4.1], 26.2 [4.0], 26.9 [4.4] 
<0.001 
<0.001 
4 of 6  
WC (cm) 
m: 94.0 [9.1], 94.9 [8.8], 95.7 [9.2], 97.0 [9.3]                                       
w: 79.6 [9.5], 80.7 [10.0], 81.5 [9.9], 82.9 [10.4] 
<0.001 
<0.001 
HC (cm) 
m: 102.3 [5.7], 102.8 [5.7], 103.0 [6.2], 103.7 [6.6]                                     
w: 102.0 [8.1] 103.2 [8.9], 103.5 [8.4], 104.7 [9.3] 
<0.001 
<0.001 
WHR 
m: 0.92 [0.06], 0.92 [0.05], 0.93 [0.05], 0.93 [0.05]                                      
w: 0.78 [0.05], 0.78 [0.06], 0.79 [0.06], 0.79 [0.06] 
<0.001 
<0.001 
BF (%) 
m: 22.5 [6.6], 23.4 [6.2], 24.3 [7.5], 25.3 [7.0]                                        
w: 37.1 [8.6], 38.9 [8.8], 40.0 [8.6], 41.6 [9.3] 
<0.001 
<0.001 
s BP (mmHg) 
m: 135.0 [16.8], 136.4 [17.7], 138.1 [17.7], 138.4 [19.0]                    
m10: 135.6 [15.1], 136.7 [15.4], 137.7 [14.9], 137.8 [15.6]                   w: 
130.9 [15.1], 132.3 [11.6], 133.4 [11.2], 134.0 [11.7]                   w10: 
131.6 [16.8], 132.6 [13.3], 133.3 [13.3], 133.1 [14.3] 
<0.001 
<0.001 
<0.001 
<0.01 
d BP (mmHg) 
m: 83.2 [12.6], 83.7 [13.3], 84.9 [13.3], 85.6 [14.3]                           
m10: 83.6 [11.3], 83.9 [11.6], 84.6 [11.2], 85.1 [11.7]                            
w: 79.2 [7.5], 80.1 [7.7], 80.7 [7.5], 81.1 [7.8]                                     
w10: 79.7 [8.4], 80.3 [8.9], 80.7 [8.9], 80.5 [9.5] 
<0.001 
<0.001 
<0.001 
<0.01 
Triglycerides 
(mmol/l) 
m: 1.70 (0.8–3.6), 1.80 (0.8–3.8), 1.82 (0.9–3.8), 1.92 (0.9–4.1)   
m10:1.73 (0.8–3.6), 1.82 (0.9–3.9), 1.80 (0.9–3.7), 1.88 (0.9–4.0)       
w: 1.38 (0.6–3.1), 1.40 (0.6–3.3), 1.49 (0.6–3.6), 1.54 (0.6–3.9) 
w10:1.42 (0.6–3.2), 1.42 (0.6–3.4), 1.48 (0.6–3.5), 1.49 (0.6–3.8) 
<0.001 
<0.01 
<0.001 
<0.001 
Cholesterol 
(mmol/l) 
m: 5.91 [1.26], 5.93 [1.33], 5.96 [1.33], 6.05 [1.43]                    
m10:5.92 [1.13], 5.93 [1.16], 5.96 [1.12], 6.04 [1.17]                          w: 
6.17 [1.13], 6.22 [0.77], 6.27 [0.75], 6.28 [0.78]                             w10: 
6.19 [1.26], 6.23 [0.89], 6.27 [0.89], 6.26 [0.95] 
<0.001 
<0.01  
0.001  
<0.01 
HDL (mmol/l) 
m: 1.28 (0.6–2.7), 1.23 (0.6–2.6), 1.22 (0.6–2.5), 1.20 (0.6–2.6)   
m10:1.27 (0.6–2.7), 1.22 (0.6–2.6), 1.22 (0.6–2.5), 1.21 (0.6–2.6)    w: 
1.63 (0.7–3.7), 1.58 (0.7–3.8), 1.57 (0.7–3.7), 1.51 (0.6–3.8)     w10: 
1.60 (0.7–3.6), 1.57 (0.7–3.7), 1.57 (0.7–3.7), 1.54 (0.6–3.9) 
<0.001 
<0.01 
<0.001 
<0.001 
LDL (mmol/l) 
m: 3.75 [0.84], 3.77 [0.89], 3.82 [0.89], 3.87 [0.95]                           
m10: 3.75 [0.75], 3.77 [0.77], 3.82 [0.75], 3.87 [0.78]                          w: 
3.82 [0.75], 3.90 [0.77], 3.93 [0.75], 3.97 [0.78]                           w10: 
3.85 [0.84], 3.91 [0.89], 3.93 [0.89], 3.95 [0.95] 
<0.001  
<0.01   
<0.001   
<0.01 
Gabriel et 148 Pearson cc between biomarker and BMI (kg/m
2) PCC: 0.18 <0.05 5 of 6  
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al.5 (2013) accelerometer measured ST (in min/d) WC (cm) PCC: 0.21 <0.01 
S BP (mmHg) PCC: 0.17 <0.05 
Insulin (mU/dl) PCC: 0.24 <0.01 
Gao et al.64 
(2007) 
455 
OR of unfavorable biomarker profile by 
quartiles of TV viewing time (0-1.5h = 
reference, 1.6-3.4h, 3.5-5.5h, 5.6-18h), 
adj. for confounders11, add. for dietary 
habits12, add. for ADL13 
Low HDL* 1 (ref), 0.9 (0.4–2.0), 1.2 (0.5–2.7), 2.5 (1.0–5.9) 
0.0211, 
0.0212, 
0.0113 
5 of 6 P-values for linear trends  
High cholesterol/           
HDL ratio* 
1 (ref), 1.2 (0.7–2.1), 1.3 (0.7–2.4), 2.0 (1.1–3.7) 
0.0111, 
0.0312, 
0.0413 
High WHR* 1 (ref), 1.6 (0.8–3.1), 2.3 (1.1–4.8), 3.9 (1.8–8.4) 
0.000311, 
0.000812, 
0.000613 
Genusso et 
al.32 (2013) 
1914 
Association of least square means of 
biomarkers with quartiles of sedentary 
hours (0-7.92, 7.93-8.17, 8.18-10.63, 
>10.64) 
BMI (kg/m2) 26.6 [0.6], 27.4 [0.5], 27.8 [0.5], 28.8 [0.4] 0.01 
5 of 6 P-values for linear trends 
WC (cm) 98.2 [1.6], 100.2 [1.3], 101.9 [1.4], 104.4 [1.0] <0.01 
Glucose (mg/dl) 115.0 [1.2], 114.8 [1.2], 119.2 [1.2], 119.8 [1.2] 0.04 
CRP (mg/dl) 0.24 [1.15], 0.24 [1.12], 0.26 [1.12], 0.34 [1.14] <0.01 
Hamer et 
al.66 (2013) 
4964 
Dose-response association for TV 
viewing (<2=Ref., 2-4, 4-6, >6h/d) and 
log transformed mean CRP values, adj. 
for age, sex14; further adj. to PA, BMI15 
CRP                                    
(log transformed) 
Ref., 0.11 (0.04 to 0.18), 0.27 (0.2 to 0.34), 0.29 (0.22 to 0.36)14              
0.04 (-0.03 to 0.1), 0.12 (0.06 to 0.19), 0.11 (0.04 to 0.17)15 
<0.001  
<0.001 
4 of 6  
Henson et 
al.39 (2013) 
558 
Regression coeff. for ST (in h/day) with 
biomarker, adj. to confounders, add. 
to PA16, add. adj. to BMI and HbA1c17 
IL-6 (pg/ml) 0.242 {0.056}, 0.231 {0.073}16, 0.212 {0.072}17 
<0.001, 
0.00216, 
0.00317 
5 of 6  
Larsen et 
al.46 (2014) 
539 
m: 135 
w: 404 
Variance (V) in mean values of 
biomarker and ST tertiles or cross-
sectional regression coefficient (csrc) 
of biomarker to ST tertiles (<2.5, 2.5-4, 
>4 sitting hours/day), unadj., adj. to 
demographics18, to CVD RF19, to BMI20, 
to inflammatory markers21 
Adiponectin (µg/ml) V: 10.4 [6.0], 9.4 [4.9], 10.8 [6.6], 10.8 [5.9] 0.032 
4 of 6 
Pos. assoc. for V of intra-
thoracic fat (p=0.018), 
intermuscular fat (p=0.001) 
and subcutaneous fat 
(p=0.034) but not sig. in 
csrc  
Intra-thoracic fat 
(cm2) 
V: 71.8 [64.1], 61.2 [50.5], 75.8 [70.9], 80.0 [66.1] 0.018 
Intermuscular fat 
(cm2) 
V: 21.4 [11.0], 19.4 [8.8], 23.5 [12.1], 21.4 [11.3] 0.001 
Subcutaneous fat 
(cm2) 
V: 253.8 [122.7], 243.4 [106.3], 273.2 [131.4], 246.6 [126.2] 0.034 
Pericardial fat (cm2) 
csrc: 3.19 (0.45 to 5.92)                                                                           
csrc18: 3.19 (0.45 to 5.92)                                                                                    
csrc19: 3.32 (0.84 to 5.81)                                                                                      
csrc20: 2.39 (0.07 to 4.72)                                                                                  
csrc21: 2.45 (0.12 to 4.77) 
0.022
0.02218
0.00919
0.04420
0.03921 
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Lee et al.33 
(2015) 
1168 
Unadj.22 as well as adj.23 average 
differences (AD) in function (as 
biomarker) between SB quartiles (Q2 
vs. Q1, Q3 vs. Q1 and Q4 vs. Q1) 
Gait speed (feet/s) 
AD22: 0.35 [0.08], 0.44 [0.08], 0.44 [0.08]                                            
AD23: 0.20 [0.07], 0.21[0.08], 0.21 [0.08] 
<0.00122   
<0.00123 
5 of 6 
 
Chair stand rate 
(stands/min) 
AD22: 3.00 [0.95], 3.28 [0.98], 5.30 [0.95]                                            
AD23: 1.85 [0.90], 1.46 [0.96], 3.43 [0.98] 
<0.00122    
0.001623 
 
Lynch et 
al.35 (2011) 
1024 
Association of SB quartiles (<7.74, 
7.74-<8.8, 8.8-<9.84, ≥9.84 h/d), adj. in 
model 124 to age; model 2 for BMI: 
ethnicity, alcohol intake, age at first 
birth, age at menarche; model 225 for 
WC: ethnicity, educational attainment, 
marital status, annual family income, 
alcohol intake, age at first birth 
BMI 
model 124: 26.7 (25.9 to 27.5), 27.6 (26.8 to 28.5), 27.6 (26.6 to 
28.6), 29.9 (28.6 to 31.2)                                                                                
model 225: 27.2 (26.4 to 27.9), 27.7 (26.9 to 28.6), 27.5 (26.6 to 
28.4), 29.3 (28.1 to 30.5) 
<0.00124    
0.0225 
5 of 6 
CRP, insulin, HOMA-IR 
showed also sig. pos. trend 
with SB quartiles, sig. after 
multivariate adj., but ns 
after adj. to WC; all results 
as marginal means for each 
quartile, back-transformed 
for all log-transformed 
outcomes 
WC 
model 124: 91.9 (89.7 to 94.2), 94.7 (92.9 to 96.5), 95.7 (93.3 to 
98.1), 102.1 (99.4 to 104.8)                                                                
model 225: 93.2 (90.8 to 95.7), 95.1 (93.1 to 97.1), 95.5 (93.2 to 
97.9), 100.5 (97.9 to 103.1) 
<0.00124
0.00325 
Reaven et 
al.6 (1991) 
641 
Mean values of age adj. biomarker by 
exercise category (none, light, 
moderate, heavy); s BP additionally 
adj. to age26, age + BMI27, age + BMI + 
alcohol + estrogen28, age+ BMI+ fasting 
insulin29,age+BMI+2h insulin30 
HR (beats/min) 66.5, 64.8, 63.9, 61.4 0.01 
3 of 6 
P-values for linear trends;  
values for D BP were ns 
when unadj. but linear 
trend adj. to same 
confounders as S BP were 
sig (p=0.00624, p=0.04425, 
p=0.04926, p=0.03427, 
p=0.02528) 
BMI (kg/m2) 26.3, 24.1, 25.1, 23.4 0.05 
S BP (mmHg) 
143.3, 136.8, 130.3, 122.6                                                                   
142.1, 135.5, 133.0, 130.326                                                                   
140.8, 135.6, 132.5, 131.327                                                                
140.7 135.6 132.5 131.428                                                                    
140.7 135.5 132.5 131.429                                                                      
140.9 134.9 131.0 131.330 
<0.001
0.003     
0.012    
0.013    
0.014
0.010 
Fasting Insulin 
(µU/ml) 
16.9, 13.7, 12.4, 11.2 0.002 
2h Insulin (µU/ml) 15.0, 88.5, 79.2, 66.2 0.001 
Stamatakis 
et al.38 
(2011) 
2765 (SR) 
649 (accel.) 
Mean values of biomarker and tertiles 
of self-reported (SR; <291, 291-394, > 
394 min/d) or accelerometer 
measured (accel.; <507, 507-571, > 
571 min/d) ST  
BMI (kg/m2) 
SR: 27.4 [4.5], 27.9 [4.6], 28.5 [5.1]                                                    
accel.: 27.1 [4.0], 28.6 [4.9], 28.5 [4.7] 
<0.01   
<0.01 
5 of 6 
P-value for one-way 
ANOVA test; a sig. pos. 
multivariate reg. coeff. was 
calculated for SR SB with 
BMI and HbA1c and similar 
for accel. measured SB with 
cholesterol and HbA1c, 
which was ns after further 
adj. 
WC (cm) 
SR: 94.8 [13.1], 96.0 [12.8], 98.3 [13.4]                                            
accel.: 93.1 [12.7], 96.5 [13.7], 99.6 [12.8] 
<0.01    
<0.01 
HDL (mmol/l) 
SR: 1.6 [0.4], 1.6 [0.4], 1.5 [0.4]                                                         
accel.: 1.7 [0.4], 1.6 [0.4], 1.5 [0.4] 
<0.01   
<0.01 
HbA1c (%) 
SR: 5.8 [0.7], 5.8 [0.6], 6.0 [0.9]                                                              
accel.: 5.8 [0.6], 5.8 [0.6], 6.0 [0.8] 
<0.01    
0.01 
Cholesterol / HDL 
ratio 
SR: 3.9 [1.0], 4.0 [1.0], 4.1 [1.2] 0.01 
*according to the definitions of Adult Treatment Panel III (ATP-III); Cholesterol/HDL ratio > 4.5 was considered as high. 
accel. = accelerometer; AD = average differences; adj. = adjusted; ADL = activities of daily living; B = baseline; BF% = percent of body fat; BMI= body mass index ; BP = blood pressure; bpm = beats per minute; cc = 
correlation coefficient; CI = confidence interval; coeff. = coefficient; CG = control group; CMRF = cardio-metabolic risk factors; CRP = C-reactive protein; csrc = cross-sectional regression coefficient; FU = follow up; 
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HbA1c = glycated hemoglobin; HC = hip circumference; HDL = high density lipoprotein; HOMA-IR = homeostatic model assessment of insulin resistance; HR = heart rate; IG = intervention group; IL = interleukin; LDL = 
low density lipoprotein; lrc = linear regression coefficient; MC = mean change; MD = mean difference; MES = metabolic syndrome; NC = neck circumference; neg. = negative; NR = not reported; OR = odds ratio; PCC = 
Pearson correlation coefficient; pos. = positive; POS = prospective observational studies; RCT = randomized controlled trials; ref = reference; S/D = systolic/diastolic;  SB = sedentary behaviour; SD = standard 
deviation; SE = standard error; sig. = significant; SR = self report; ST = sedentary time; TNF-a = tumor necrosis factor alpha; unadj. = unadjusted; V = Variance; WC= waist circumference; WHR = waist to hip ratio 
 
 
Appendix 1 – Search strategy 
concepts  search terms 
sedentariness  seden* OR television OR accelerometer OR pedometer 
age age OR aging OR elderly OR older 
biomarkers bone biomarker OR biomarker OR CRP OR interleukin OR endocrine OR diabetes 
OR insulin OR cardiovascular OR CNS OR central nervous system OR neurological 
OR hormones OR inflammation OR hematology OR blood OR liquor OR epigenetic 
OR genetic OR DNA OR RNA or ultrasound OR BIA or bioelectrical OR caliper OR 
stem cell OR cerebrovascular OR cancer OR cytokine OR mitochondr* OR immune 
OR protein OR urine OR muscle OR gait OR factor OR transcription OR strength 
OR handgrip OR oncology OR nephrology OR men health OR women health OR 
COPD OR pulmonary OR lung OR asthma OR glucose OR GID OR gastrointestinal 
OR gastric OR lipoprotein OR anabol OR katabol OR thyroid OR steroid OR 
metabolic OR testosterone OR estrogen 
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Appendix 2 - Definitions 
Accelerometer An instrument for measuring the acceleration of a 
moving body 
Biomarker A characteristic that is objectively measured and 
evaluated as an indicator of normal biological 
processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention 
Moderate-vigorous physical activity Physical activity performed at intensity ≥3 Metabolic 
Equivalents (METs) 
Sedentary behaviour Activities with an energy expenditure ≤ 1.5 Metabolic 
Equivalents (METs) while in a sitting or reclining 
posture during waking hours; not simply the absence 
of physical activity 
 
